Neurology® Podcast

Parkinson's & parkinsonism disorders. Lesson of the Week interviews from January 2014.

1) Effects of cannabis on cognition in patients with multiple sclerosis and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Anthony Feinstein about his paper on the effects of cannabis on cognition in patients with multiple sclerosis. Dr. James Addington is reading our e-Pearl of the week about spinal dural arteriovenous fistula. In the next part of the podcast Dr. Mike Brogan interviews Dr. Claude Hemphill about the management of intracranial hypertension. The participants had nothing to disclose except Drs. Feinstein, Addington and Hemphill.Dr. Feinstein serves as an editorial board member of Multiple Sclerosis and African Journal of Psychiatry; receives royalties from the publication of the book The Clinical Neuropsychiatry of Multiple Sclerosis; performs neuropsychiatric evaluation, cognitive testing, brain imaging in neuropsychiatry clinical practice; receives research support from Biogen Idec, Canadian Institute of Health Research, Multiple Sclerosis Society of Canada and University of Toronto; received honoraria for lectures from Merck Serono, Novartis and Teva Pharmaceutical Industries Ltd.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Hemphill serves as an editorial board member of Neurocritical Care; holds stock options for serving on the scientific advisory board for Ornim Medical; receives research support from Cerebrotech Medical; funding as PI for hub site for Neurological Emergencies Treatment Trials Network; received a one-time speaking honorarium from Besins Critical Care, LLC and honoraria from Edge Therapeutics, Inc. for consulting; gave expert witness review and testimony on various cases related to stroke and neurocritical care.

1) Cerebrospinal fluid AB42 predicting early onset Parkinson disease and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Barrett interviews Dr. Henrik Zetterberg about his paper on cerebrospinal fluid A?42 predicting early onset Parkinson disease. Dr. James Addington is reading our e-Pearl of the week about Kennedy disease. In the next part of the podcast Dr. Mike Brogan interviews Dr. Laurie Gutmann about critical illness in polyneuropathy and myopathy. The participants had nothing to disclose except Drs. Zetterberg, Addington and Gutmann.Dr. Zetterberg serves as Senior Editor of the Journal of Alzheimer's disease; serves as Associate Editor of Alzheimer and Dementia; receives research support from the Swedish Research Council and Swedish State Support for Clinical Research. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gutmann receives royalties from Up-to-Date Online from the publication of Hypokalemic and Hyperkalemic Periodic Paralysis; receives research support from Alexion Pharmaceuticals, Inc. and the NIH.

1) Venous thromboembolism in amyotrophic lateral sclerosis and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Lorne Zinman about his paper on venous thromboembolism in amyotrophic lateral sclerosis. Dr. James Addington is reading our e-Pearl of the week about SCN4A mutations. In the next part of the podcast Dr. Mike Brogan interviews Dr. Thomas Bleck about the management of status epilepticus in critical care. The participants had nothing to disclose except Drs. Burns, Zinman, Addington and Bleck.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Zinman serves on the scientific advisory board for the Data and Safety Monitoring Board NIH sponsored Tamoxiphen/Creatine ALS Study (non-profit entity); receives research support from the Garfield Weston Foundation, Public Health Agency of Canada, Canadian Institute of Health Research, ALS Society of Canada and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bleck serves on the data safety and monitoring boards of the NIH sponsored RAMPART and ProTECT trials.

Utility of an immunotherapy trial in the evaluation of patients with presumed autoimmune epilepsy and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Sean Pittock about his paper on the utility of an immunotherapy trial in the evaluation of patients with presumed autoimmune epilepsy. Dr. James Addington is reading our e-Pearl of the week about logopenic-variant primary progressive aphasia. In the next part of the podcast Dr. Mike Brogan interviews Dr. Pratik Pandharipande about delirium in acute brain dysfunction in critically ill patients. The participants had nothing to disclose except Drs. Pandharipande, Pittock and Addington.Dr. Pandharipande received research support from Hospira Inc. and the NIH.Dr. Pittock received research support from Alexion Pharmaceuticals, Inc.; Guthy Jackson Charitable Foundation and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.

Treatment of Movement disorders. Lesson of the Week interviews from May 2013

1) AAN paper on efficacy and safety of the therapeutic use of medical marijuana (Cannabis) in selected neurologic disorders and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Suski interviews Dr. Barbara Koppel about the AAN paper on efficacy and safety of the therapeutic use of medical marijuana (Cannabis) in selected neurologic disorders. Dr. Adam Numis is reading our e-Pearl of the week about myoclonic astatic epilepsy. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Greg Bergey about epilepsy therapeutics: Beyond medications for the refractory patient. The participants had nothing to disclose except Drs. Koppel, Numis and Bergey.Dr. Koppel serves as an editorial board member of Clinical Neurology.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bergey was an expert witness in medicolegal activity over the past two years and receives research support from the NIH.

1) Migraine trait symptoms in migraine with and without aura and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Sowell interviews Dr. Tim Jürgens about his paper on migraine trait symptoms in migraine with and without aura. Dr. Adam Numis is reading our e-Pearl of the week about idiopathic normal pressure hydrocephalus. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Elinor Ben-Menachem about epilepsy therapeutics: Vigabatrin. The participants had nothing to disclose except Drs. Jürgens, Numis and Ben-Menachem.Dr. Jurgens serves as an editorial board member of ISRN Pain, serves as Visiting Editor of the Journal of Headache and Pain; is a consultant for Autonomic Technologies, Inc.; received speaker honoraria from Allergan, Inc., Pfizer Inc, MSD (commercial), Autonomic Technologies, Inc., DAGFA (non-profit), Kinderhospiz Sternenbrucke (non-commercial), received funding for Travel from MSD (commercial), Autonomic Technologies, Inc., DAGFA (non-profit), Kinderhospiz Sternenbrucke (non-commercial), Deutsche Migrane- und Kopfschmerzgesellschaft (non-commercial),) Deutsche Schmerzgesellschaft (non-commercial); serves as a board member of Deutsche Migrane- und Kopfschmerzgesellschaft; receives research support from Allergan, Inc. and Deutsche Migrane- und Kopfschmerzgesellschaft.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ben-Menachem serves as Editor of Acta Neurologica Scanidnavica; receives funding for travel from Eisai Inc., UCB, ElectroCore Medical, LLC.

1) Skin nerve a-synuclein deposits being a biomarker for idiopathic Parkinson disease and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Ratliff interviews Dr. Vincenzo Donadio about his paper on skin nerve ?-synuclein deposits being a biomarker for idiopathic Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about cognitive impairment in pediatric multiple sclerosis. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Nathan Fountain about epilepsy therapeutics: Lacosamide. The participants had nothing to disclose except Drs. Fountain and Numis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.

1) Fingolimod after natalizumab and the risk of short-term relapse and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Vilija Jokubaitis about her paper on fingolimod after natalizumab and the risk of short-term relapse. Dr. Adam Numis is reading our e-Pearl of the week about cardiac cephalgia. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Madeline Fields about epilepsy therapeutics: Clobazam. The participants had nothing to disclose except Drs. Keegan, Jokubaitis and Numis.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Jokubaitis received funding for travel to speak at a conference from Novartis, receives research support from MSBase Foundation and National Health and Medical Research Council.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.